PT - JOURNAL ARTICLE AU - German, Jakob AU - Cordioli, Mattia AU - Tozzo, Veronica AU - Urbut, Sarah AU - Arumäe, Kadri AU - Smit, Roelof A.J. AU - Lee, Jiwoo AU - Li, Josephine H. AU - Janucik, Adrian AU - Ding, Yi AU - Akinkuolie, Akintunde AU - Heyne, Henrike AU - Eoli, Andrea AU - Saad, Chadi AU - Al-Sarraj, Yasser AU - Abdel-latif, Rania AU - Barry, Alexandra AU - Wang, Zhe AU - , AU - Natarajan, Pradeep AU - Ripatti, Samuli AU - Philippakis, Anthony AU - Szczerbinski, Lukasz AU - Pasaniuc, Bogdan AU - Mbarek, Hamdi AU - Loos, Ruth J.F. AU - Vainik, Uku AU - Ganna, Andrea TI - Association between plausible genetic factors and weight loss from GLP1-RA and bariatric surgery: a multi-ancestry study in 10 960 individuals from 9 biobanks AID - 10.1101/2024.09.11.24313458 DP - 2024 Jan 01 TA - medRxiv PG - 2024.09.11.24313458 4099 - http://medrxiv.org/content/early/2024/09/12/2024.09.11.24313458.short 4100 - http://medrxiv.org/content/early/2024/09/12/2024.09.11.24313458.full AB - Obesity is a significant public health concern. GLP-1 receptor agonists (GLP1-RA), predominantly in use as a type 2 diabetes treatment, are a promising pharmacological approach for weight loss, while bariatric surgery (BS) remains a durable, but invasive, intervention. Despite observed heterogeneity in weight loss effects, the genetic effects on weight loss from GLP1-RA and BS have not been extensively explored in large sample sizes, and most studies have focused on differences in race and ethnicity, rather than genetic ancestry. We studied whether genetic factors, previously shown to affect body weight, impact weight loss due to GLP1-RA therapy or BS in 10,960 individuals from 9 multi-ancestry biobank studies in 6 countries. The average weight change between 6 and 12 months from therapy initiation was -3.93% for GLP1-RA users, with marginal differences across genetic ancestries. For BS patients the weight change between 6 and 48 months from the operation was -21.17%. There were no significant associations between weight loss due to GLP1-RA and polygenic scores for BMI or type 2 diabetes or specific missense variants in the GLP1R, PCSK1 and APOE genes, after multiple-testing correction. However, a higher polygenic score for BMI was significantly linked to lower weight loss after BS (+0.7% for 1 standard deviation change in the polygenic score, P = 1.24×10-4). In contrast, higher weight at baseline was associated with greater weight loss. Our findings suggest that existing polygenic scores related to weight and type 2 diabetes and missense variants in the drug target gene do not have a large impact on GLP1-RA effectiveness. Our results also confirm the effectiveness of these treatments across all major continental ancestry groups considered.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was in part supported by funding from the Eric and Wendy Schmidt Center at the Broad Institute of MIT and Harvard.This study was in part supported by funding from Estonian Research Council's personal research funding start-up grant PSG759 and European Research Council' starting grant under the grant agreement no 101117251 (OBECAUSE).This study was in part supported by NIDDK K23 DK131345.This work was further financially supported in part by National Institutes of Health awards U01HG011715, R01HG009120 and R01MH115676.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB neededI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data utilized in this study can be accessed by applying to each of the participating studies individually. Additional details are provided in the manuscript under the Data Availability section.